Phio Pharmaceuticals Corp. PHIO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -18.10%
- 1 year
- -58.25%
- Open
- 0.86
- Prev close
- 0.8626
- Mkt cap
- 9.99M
- Vol
- 66.66K
- Avg vol
- 128.05K
- EPS
- -1.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.85
- High
- 0.8767
- Forward P/E
- 0.07
- Beta
- 1.47
- Short ratio
- 0.50
- Inst. own
- 3.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.76
- 200-d avg
- 4.62
- 1y target
- 0.00
6M chart
Signals (28)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 3 days ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 4 weeks ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 29, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| SMA: Bullish | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 7, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 18, 2026 | 4 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
Key statistics
- Market cap
- 2.35M
- Enterprise value
- -2.80M
- Trailing P/E
- 0.00
- Forward P/E
- 0.07
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.12
- EPS (TTM)
- -9.75
- Beta
- 1.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.73M
- Total cash
- 4.70M
- Total debt
- 0
- Return on equity
- -126.86%
- Shares outstanding
- 1.06M
- Short % of float
- 6.00%
- 50-day average
- 2.76
- 200-day average
- 4.62
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.54 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -4.59 | -3.62 | +0.97 | +21.13% |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -4.23 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -1.53 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -12.87 | -10.26 | +2.61 | +20.28% |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -13.23 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 16, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- phiopharma.com
News
Your note
Sign in to keep a note on PHIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BITTERMAN ROBERT J | Chief Executive Officer | Stock Award(Grant) | Sep 10, 2024 | 17,832 |
| BRADFORD PATRICIA A | Director | Stock Award(Grant) | Sep 10, 2024 | 8,000 |
| CAUWENBERGH GEERT | Director | Stock Award(Grant) | Feb 16, 2023 | 4,235 |
| FERRARA ROBERT L | Director | Stock Award(Grant) | Sep 10, 2024 | 10,000 |
| FREEMAN JONATHAN E PH.D. | Director | Stock Award(Grant) | Sep 10, 2024 | 1,000 |
| KONTULIS CAITLIN | Officer | Stock Award(Grant) | Feb 16, 2023 | 12,494 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 2.38% | 25,131 | 56.04K | Sep 29, 2024 |
| UBS Group AG | 0.16% | 1,685 | 3.76K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.11% | 1,174 | 2.62K | Sep 29, 2024 |
| Nordwand Advisors, LLC | 0.05% | 500 | 1.11K | Sep 29, 2024 |
| Activest Wealth Management | 0.00% | 9 | 20 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 7 | 15 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.41% | 4,290 | 9.57K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.26% | 2,707 | 6.04K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.15% | 1,582 | 3.53K | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 4 | 8 | Sep 29, 2024 |